3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with apomorphine in 7 studies
| Studies (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Trials (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Recent Studies (post-2010) (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Studies (apomorphine) | Trials (apomorphine) | Recent Studies (post-2010) (apomorphine) |
|---|---|---|---|---|---|
| 330 | 40 | 33 | 9,205 | 287 | 780 |
| Protein | Taxonomy | 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide (IC50) | apomorphine (IC50) |
|---|---|---|---|
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | 0.22 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0146 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D | Rattus norvegicus (Norway rat) | 0.4744 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 0.3385 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(1B) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0813 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.205 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 1.35 | |
| D | Bos taurus (cattle) | 0.3385 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, G; Gasser, T; Kirsch, CM; Oertel, WH; Schwarz, J; Tatsch, K; Trenkwalder, C | 1 |
| Cordes, M; Hierholzer, J; Poewe, W; Schelosky, L; Wissel, J | 1 |
| Böck, JC; Cordes, M; David, I; Hierholzer, J; Horowski, R; Poewe, W; Sander, B; Schelosky, L | 1 |
| Arnold, G; Gasser, T; Kirsch, CM; Oertel, WH; Schwarz, J; Tatsch, K | 1 |
| Castelli, L; Cordes, M; Felix, R; Hierholzer, J; Poewe, W; Schelosky, L | 1 |
| Arnold, G; Gasser, T; Oertel, WH; Schwarz, J; Tatsch, K | 1 |
| Arnold, G; Kraft, E; Oertel, WH; Schwarz, J; Tatsch, K; Vogl, T | 1 |
1 trial(s) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and apomorphine
| Article | Year |
|---|---|
[123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.
Topics: Adult; Aged; Apomorphine; Atrophy; Benzamides; Binding Sites; Cerebral Cortex; Dopamine; Dopamine Agonists; Dopamine Antagonists; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease; Predictive Value of Tests; Putamen; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1997 |
6 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and apomorphine
| Article | Year |
|---|---|
123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Benzamides; Humans; Iodine Radioisotopes; Levodopa; Middle Aged; Parkinson Disease; Pyrrolidines; Receptors, Dopamine; Tomography, Emission-Computed, Single-Photon | 1992 |
Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.
Topics: Adult; Aged; Apomorphine; Basal Ganglia; Benzamides; Binding Sites; Brain; Corpus Striatum; Female; Humans; Male; Middle Aged; Parkinson Disease; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1993 |
[The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Contrast Media; Diagnosis, Differential; Dopamine D2 Receptor Antagonists; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Parkinson Disease; Pyrrolidines; Time Factors; Tomography, Emission-Computed, Single-Photon | 1993 |
IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Apomorphine; Benzamides; Corpus Striatum; Dopamine D2 Receptor Antagonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Pyrrolidines; Receptors, Dopamine D1; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1993 |
[Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs].
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Brain; Contrast Media; Dopamine Agonists; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Parkinson Disease; Pyrrolidines; Tomography, Emission-Computed, Single-Photon | 1996 |
Relative quantification of signal on T2-weighted images in the basal ganglia: limited value in differential diagnosis of patients with parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Basal Ganglia; Benzamides; Contrast Media; Diagnosis, Differential; Dopamine Antagonists; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease; Prospective Studies; Pyrrolidines; Tomography, Emission-Computed, Single-Photon | 1999 |